Understanding how saccharide spatial arrangement governs multivalent glycan recognition is critical, yet quantitative design principles linking glycan geometry to binding affinity remain poorly define...

Title: Expanding Access to Carbohydrates: N-Glycan Isolation and Synthetic Approaches to Glycomimetics Abstract: Our research group focuses on two research streams: the scalable isolation of N-glyca...

GlycoMimetics, Inc. (NASDAQ:GLYC – Get Free Report) crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $0.23 and traded as high as $0.25. GlycoMimetics shares last traded at $0.23, with a volume of 536,863 shares trading hands. Wall Street Analyst Weigh In Several […]

Equities research analysts at StockNews.com initiated coverage on shares of GlycoMimetics (NASDAQ:GLYC – Get Free Report) in a research note issued on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock. Separately, Cantor Fitzgerald initiated coverage on shares of GlycoMimetics in a research report on Friday, March 21st. They issued an “overweight” […]

Glycans are vital macromolecules with diverse biological roles, decoded by lectins – specialized carbohydrate-binding proteins crucial in pathogenesis. The WHO identifies bacterial antimicrobial resistance (AMR) as a critical global health challenge, necessitating innovative strategies that also target non-antibiotic pathways. Recent studies highlight bacterial lectins as key players in pathogenesis and promising therapeutic targets, with early clinical success using glycomimetics and vaccines to treat and prevent AMR-related infections. This review covers the current knowledge on bacterial lectins, their classifications, and roles in host recognition and adhesion, biofilm formation, cytotoxicity, and host immune evasion, with examples of well-characterized lectins. It also explores their therapeutic potential and highlights novel lectins with unknown functions, encouraging further research.

Incyte antibody INCA033989 shows success in thrombocythemia patients, while D&D Pharmatech's DD01 and Jasper's briquilimab report positive trial results. Crescent acquires GlycoMimetics.

Gem-C,C-glycosides — C-glycosides characterized by two carbon substituents at the pseudo-anomeric position — constitute a structurally distinctive class of glycomimetics with growing relevance in natu...

Reported Friday, Jun 13 - 7:50pm EDT (TheFly subscription required to read more.)

Reported Thursday, Jun 5 - 4:02pm EDT (TheFly subscription required to read more.)

The Investor Relations website contains information about GlycoMimetics, Inc.'s business for stockholders, potential investors, and financial analysts.

GlycoMimetics fails phase 3 blood cancer trial, causing investors to sour on stock  Fierce Biotech